Optimi Health Corp. · CSE:OPTI

Optimi Health — Investor Presentation (November 2026)

16 slides from Optimi Health's investor presentation, November 2026

  1. Slide 1: Investor Presentation

    NASDAQ: OPTH | CSE: OPTI | FSE: 8BN Investor Presentation November 2026 Naturally derived psychedelic solutions to address significant global unmet needs

  2. Slide 2: Disclaimer & forward-looking statements

    Disclaimer & forward-looking statements This presentation has been prepared by Optimi Health Corp. ("Optimi" or the "Company") for informational purposes only. It is based on information from the Company and publicly available sources, including the Company’s public filings with applicable securitie

  3. Slide 3: Natural medicines on a path to registration

    Natural medicines on a path to registration Investment highlights Phase 2 and Phase 3 trials starting Natural psilocybin (OPTI-101): Phase 2 in MDD, up to 200 patients in 2027 MDMA (OPTI-201): Phase 3 in PTSD, up to 100 patients To our knowledge, one of the only naturally extracted psilocybin in com

  4. Slide 4: Legacy options have limited efficacy and high relapse rates

    Lead program targets a large unmet need Legacy options have limited efficacy and high relapse rates4 322M People have MDD worldwide1 23M Americans experience MDD annually2 12M Americans treated for MDD in the last year2 1/3 (4M) Considered TRD (fail 2+ antidepressants)3 1. World Health Organization,

  5. Slide 5: Clinical path to registration

    Clinical path to registration Pipeline Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Dosing expected to begin OPTI-101 MDD Q1 2027; topline data expected H1 2028 Canadian trial initiation and OPTI-201 PTSD planned U.S. IND filing in 2027 OPTI-101: Naturally derived psilocybin OPTI-201:

  6. Slide 6: OPTI-101: Psilocybin

    Natural psilocybin extract OPTI-101: Psilocybin Natural extract supplied to patients in Australia What is psilocybin? Naturally occurring psychedelic compound found in certain fungi, studied for its effects on neuroplasticity and brain network activity Clinically studied for treatment-resistant depr

  7. Slide 7: OPTI-101: Psilocybin Phase 2 clinical trial

    Phase 2 clinical trial OPTI-101: Psilocybin Major depressive disorder (MDD) Supported by prior clinical data Health Canada-authorized trial, starting 2027 Ph 1 Ph 2 Ph 3 Design Endpoint Timing Patients Single supervised session Change from baseline in Dosing expected to begin Up to 200 patients with

  8. Slide 8: OPTI-201: MDMA

    MDMA capsules OPTI-201: MDMA Supplying patients in Australia and Canada What is MDMA? Psychoactive compound studied for its effects on emotional processing, fear responses and the therapeutic alliance MDMA-assisted therapy received FDA Breakthrough Therapy designation for PTSD (2017, MAPS/Lykos prog

  9. Slide 9: OPTI-201: MDMA Phase 3 clinical trial

    Phase 3 clinical trial OPTI-201: MDMA Post-traumatic stress disorder (PTSD) Supported by prior clinical data Health Canada-authorized trial, starting 2027 Ph 1 Ph 2 Ph 3 Design Endpoint Timing Patients Two supervised sessions Change from baseline in Canadian trial initiation and Up to 100, with a fo

  10. Slide 10: What the trials unlock

    The clinical opportunity What the trials unlock 1 Canada: NOC/c pathway 2 United States: FDA pathway Conditional approval for serious conditions based on promising evidence of ICH-standard Canadian data designed to support a U.S. Phase 3 effectiveness, with confirmatory studies required Executive Or

  11. Slide 11: Australia proved the model

    Proof of model Australia proved the model Nearly 5,000 doses shipped as of Q3 2026 Repeat orders scaling with distribution partners in Australia Capacity to manufacture millions of doses for export 01 02 03 04 Optimi exports from Canada to Local pharmacy delivers Patient receives treatment at DVA fu

  12. Slide 12: Vertically integrated GMP manufacturing

    How we make it Vertically integrated GMP manufacturing Cultivation & sourcing Extraction & API Formulation QC & release Export & dispensing Sterile cultivation of Psilocybe → Natural psilocybin extraction → Dose-titrated encapsulation at → HPLC-MS verification, USP → International narcotic permits;

  13. Slide 13: How Optimi wins in each scenario

    Strategic position How Optimi wins in each scenario 1 FDA approves a psilocybin drug (possible 2026–27) 2 FDA approvals slip Executive Order directs an expedited DEA scheduling review Existing supply business continues U.S. clinic infrastructure builds out Australia expands; Canada’s Special Access

  14. Slide 14: Accomplishments & catalysts

    Momentum Accomplishments & catalysts Delivered in 2026 to date Catalysts ahead Completed 2026 production of MDMA and psilocybin; Australian import permits Continued Australian expansion under the broadened prescriber framework obtained Phase 2 psilocybin trial (MDD): dosing Q1 to Q3 2027 MDMA and ps

  15. Slide 15: Leadership

    Experienced team Leadership Executives, directors, and strategic advisors who built and scaled global consumer and pharmaceutical brands JJ Wilson Dane Stevens Bryan Safarik Dr. Michael Blough Chairman Chief Executive Officer & Director Chief Operating Officer & Director Chief Clinical Development O

  16. Slide 16: Naturally derived psychedelic solutions to address significant global unmet needs

    Naturally derived psychedelic solutions to address significant global unmet needs 01 02 03 Phase 2 and 3 trials Supplying patients Low-cost natural in 2027 today supply NASDAQ: OPTH | CSE: OPTI | FSE: 8BN

Optimi Health — Investor Presentation (November 2026) on 6ix